AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18575048 — intervention group
Group type: COMPARATOR
Intervention: Intravenous opioid analgesia (morphine hydrochloride 0.1 mg/kg IV every 4-6 hours as needed, with or without ketorolac trometamol up to 90 mg/day IV)
Number of subjects: 188
Study 16020979 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine plus oral etoposide (GE group)
Number of subjects: 89
Study 16020979 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine plus cisplatin (GP group)
Number of subjects: 89
Study 12464648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy screening
Number of subjects: 56532
Study 10493324 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (900 to 1800 mg/d)
Number of subjects: 21
Study 10493324 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (25 to 75 mg/d)
Number of subjects: 21
Study 10493324 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 21
Study 10493324 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 21
Study 10493324 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin and Amitriptyline
Number of subjects: 21
Study 8952651 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening with faecal occult blood testing
Number of subjects: 0
Study 8952651 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 1775082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol (TTS 50) at 50 micrograms/day
Number of subjects: 50
Study 1775082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 50
Study 7282752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 15
Study 7282752 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 15
Study 7282752 — intervention group
Group type: COMPARATOR
Intervention: Control (before administration of hydralazine or isosorbide dinitrate)
Number of subjects: 15
Study 31306527 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifarotene 50 μg/g cream
Number of subjects: 453
Study 30341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 75
Study 30341767 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 75
Study 30341767 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine
Number of subjects: 75
Study 28077588 — intervention group
Group type: EXPERIMENTAL
Intervention: SeV-Gag primed followed by Ad35-GRIN boost (SLA)
Number of subjects: 65
Study 28077588 — intervention group
Group type: EXPERIMENTAL
Intervention: SeV-Gag primed followed by Ad35-GRIN boost (SHA)
Number of subjects: 65
Study 28077588 — intervention group
Group type: COMPARATOR
Intervention: Ad35-GRIN alone (Control)
Number of subjects: 65
Study 28077588 — intervention group
Group type: COMPARATOR
Intervention: SeV-Gag alone (Control)
Number of subjects: 65
Study 28077588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN primed followed by SeV-Gag boost (ASH)
Number of subjects: 65
Study 28077588 — intervention group
Group type: EXPERIMENTAL
Intervention: SeV-Gag primed followed by SeV-Gag boost (SHSH)
Number of subjects: 65
Study 25891302 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise (EX group)
Number of subjects: 100
Study 25891302 — intervention group
Group type: COMPARATOR
Intervention: Printed education material regarding physical activity (PA group)
Number of subjects: 100
Study 24241092 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (600 mg) and vitamin E (400 IU)
Number of subjects: 85
Study 24241092 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU) with and without ALA
Number of subjects: 85
Study 24241092 — intervention group
Group type: COMPARATOR
Intervention: All groups (including placebo)
Number of subjects: 85
Study 21798991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day)
Number of subjects: 227
Study 21798991 — intervention group
Group type: COMPARATOR
Intervention: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days)
Number of subjects: 227
Study 21798991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) among women without previous vaginal deliveries
Number of subjects: 227
Study 21798991 — intervention group
Group type: COMPARATOR
Intervention: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) among women without previous vaginal deliveries
Number of subjects: 227
Study 21798991 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) when gestation exceeded 16 weeks
Number of subjects: 227
Study 21798991 — intervention group
Group type: COMPARATOR
Intervention: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) when gestation exceeded 16 weeks
Number of subjects: 227
Study 19846849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified blood-pressure control (target 24-hour mean arterial pressure below the 50th percentile)
Number of subjects: 385
Study 19846849 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood-pressure control (mean arterial pressure in the 50th to 95th percentile)
Number of subjects: 385
Study 19846849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 385
Study 19846849 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified blood-pressure control
Number of subjects: 385
Study 17584910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy regimen consisting of vincristine (2 mg/m2), doxorubicin (90 mg/m2), cyclophosphamide (2,200 mg/m2) and ifosfamide (2,800 mg/m2/day x 5 days), etoposide (100 mg/m2/day x 5 days) over 51 weeks
Number of subjects: 60
Study 15502293 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training through a multi‐faceted injury prevention program (4 hours)
Number of subjects: 16
Study 15502293 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) received intervention during weeks 18-21
Number of subjects: 16
Study 11162418 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 16
Study 11162418 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 16
Study 11162418 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 microg
Number of subjects: 16
Study 11162418 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 800 microg
Number of subjects: 16
Study 9580247 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Lispro (IL)
Number of subjects: 10
Study 9580247 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (RI)
Number of subjects: 10
Study 8155220 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 10-minute perineal massage
Number of subjects: 46
Study 8155220 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 46
Study 8155220 — intervention group
Group type: COMPARATOR
Intervention: Attending physician awareness of group assignment
Number of subjects: 46
Study 2837078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g elemental phosphorus as neutral sodium‐potassium phosphate in grape juice or in water
Number of subjects: 18
Study 2837078 — intervention group
Group type: COMPARATOR
Intervention: 1.7 g NaCl in juice
Number of subjects: 18
Study 2837078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g phosphorus in juice
Number of subjects: 18
Study 2837078 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-1.5 g phosphorus
Number of subjects: 18
Study 30535271 — intervention group
Group type: EXPERIMENTAL
Intervention: Spondee singlets
Number of subjects: 36
Study 30535271 — intervention group
Group type: EXPERIMENTAL
Intervention: Spondee triplets
Number of subjects: 36
Study 30535271 — intervention group
Group type: EXPERIMENTAL
Intervention: Connected discourse
Number of subjects: 36
Study 30535271 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up experiment with older adults (not specified as control)
Number of subjects: 36
Study 29722944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tadalafil once daily
Number of subjects: 76
Study 29722944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tadalafil on demand
Number of subjects: 76
Study 29722944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tadalafil once-daily + on-demand
Number of subjects: 76
Study 25582563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training
Number of subjects: 26
Study 25582563 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 26
Study 25582563 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 26
Study 25582563 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 26
Study 23391033 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Number of subjects: 50
Study 23391033 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Number of subjects: 50
Study 23391033 — intervention group
Group type: EXPERIMENTAL
Intervention: Inlay preparations, zirconia ceramic (ICE Zirkon)
Number of subjects: 50
Study 23391033 — intervention group
Group type: EXPERIMENTAL
Intervention: Onlay preparations, zirconia ceramic (ICE Zirkon)
Number of subjects: 50
Study 23391033 — intervention group
Group type: COMPARATOR
Intervention: Intact teeth (control)
Number of subjects: 50
Study 20530505 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-infarct-related artery (IRA) PCI
Number of subjects: 2201
Study 20530505 — intervention group
Group type: COMPARATOR
Intervention: IRA-only PCI
Number of subjects: 2201
Study 18728526 — intervention group
Group type: COMPARATOR
Intervention: 1 g fructose
Number of subjects: 32
Study 18728526 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g fructose
Number of subjects: 32
Study 18728526 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 g fructose
Number of subjects: 32
Study 18728526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose restriction after positive test results
Number of subjects: 32
Study 16608040 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg per day (group A)
Number of subjects: 38
Study 16608040 — intervention group
Group type: COMPARATOR
Intervention: No antifibrotic agent (group B)
Number of subjects: 38
Study 14594883 — intervention group
Group type: COMPARATOR
Intervention: Control group (without heart disease)
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HF patients
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-HF patients
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-HF patients
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-HF (multivariate predictors)
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-HF (multivariate predictors)
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HF heart disease (multivariate predictors)
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction (multivariate predictors)
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: No response to questionnaire (multivariate predictors)
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher age (for every 10 years) (multivariate predictors)
Number of subjects: 2157
Study 14594883 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex (multivariate predictors)
Number of subjects: 2157
Study 10697443 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 54
Study 8638516 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrained knuckle height isoinertial strength (RK)
Number of subjects: 22
Study 8638516 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-wise multiple regression analysis
Number of subjects: 22
Study 8638516 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation on a different sample (N = 10)
Number of subjects: 22
Study 8638516 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle activation levels
Number of subjects: 22
Study 1426099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (HDAra-C) as a single agent for induction therapy
Number of subjects: 143
Study 1426099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Ara-C (HDAra-C) plus mAMSA
Number of subjects: 143
Study 4001887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lewis blood group testing in patients with primary Sjögren's syndrome
Number of subjects: 75
Study 4001887 — intervention group
Group type: COMPARATOR
Intervention: Control group (general population)
Number of subjects: 75
Study 30452713 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole treatment (3-monthly for 1 year)
Number of subjects: 300
Study 30452713 — intervention group
Group type: COMPARATOR
Intervention: Control (uninfected subjects)
Number of subjects: 300
Study 29215519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical Foley catheter plus oxytocin infusion
Number of subjects: 201
Study 29215519 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion alone
Number of subjects: 201
Study 26868849 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 30
Study 26868849 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid/betamethasone
Number of subjects: 30
Study 26868849 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol/betamethasone
Number of subjects: 30
Study 25238439 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with levobupivacaine (150 mg), ketorolac (30 mg), and adrenaline (0.5 mg)
Number of subjects: 56
Study 25238439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infiltration)
Number of subjects: 56
Study 25238439 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 56
Study 21868390 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger group
Number of subjects: 0
Study 21868390 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants
Number of subjects: 0
Study 20012089 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression profiling (GEP) using CupPrint(TM)
Number of subjects: 43
Study 20012089 — intervention group
Group type: COMPARATOR
Intervention: Immunohistochemistry (IHC)
Number of subjects: 43
Study 20012089 — intervention group
Group type: COMPARATOR
Intervention: Gene expression profiling (GEP)
Number of subjects: 43
Study 20012089 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IHC and GEP
Number of subjects: 43
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers employed in agriculture
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with probable exposure to pesticides
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers with indirect contact with agricultural products (transport and retail)
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers aged below 25
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of genital disease in the father
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of genital disease in the mother
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight of the infant
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers consuming alcohol during pregnancy
Number of subjects: 293
Study 16824044 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples who conceived while using condoms
Number of subjects: 293
Study 15836710 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily
Number of subjects: 94
Study 15836710 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg once daily with cisapride 20 mg twice a day
Number of subjects: 94
Study 12601321 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of vestibular rehabilitation (VR)
Number of subjects: 124
Study 12601321 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks of strengthening exercise (Control)
Number of subjects: 124
Study 12601321 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups had vestibular rehabilitation for 12 weeks
Number of subjects: 124
Study 10480285 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week for 6 weeks
Number of subjects: 25
Study 10480285 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rHuEpo)
Number of subjects: 25
Study 10480285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rHuEpo)
Number of subjects: 25
Study 8728306 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan potassium
Number of subjects: 75
Study 8728306 — intervention group
Group type: COMPARATOR
Intervention: Enalapril maleate
Number of subjects: 75
Study 1919425 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion (108 +/- 6 micrograms kg-1 min-1)
Number of subjects: 8
Study 1919425 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 8
Study 6356950 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective proximal vagotomy with complete ulcer excision
Number of subjects: 30
Study 6356950 — intervention group
Group type: COMPARATOR
Intervention: Partial gastrectomy with gastroduodenostomy
Number of subjects: 30
Study 30341746 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of healthcare waste management
Number of subjects: 400
Study 30341746 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice of healthcare waste management
Number of subjects: 400
Study 30341746 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 35-44 years, nurses, midwives, medical laboratory personnel
Number of subjects: 400
Study 30341746 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational status
Number of subjects: 400
Study 30341746 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall knowledge and practice
Number of subjects: 400
Study 29499745 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment, traditional EA treatment with de-qi sensation, 3 times per week for 12 sessions over 4 weeks.
Number of subjects: 62
Study 29499745 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture treatment, without needle penetration and electrostimulation, 3 times per week for 12 sessions over 4 weeks.
Number of subjects: 62
Study 27602394 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial thickness double pedicle graft
Number of subjects: 8
Study 27602394 — intervention group
Group type: COMPARATOR
Intervention: Full thickness double pedicle graft
Number of subjects: 8
Study 24463448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (n = 12)
Number of subjects: 18
Study 24463448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 18
Study 23167852 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature-Attribute-Matching-plus-User-Feedback strategy
Number of subjects: 51
Study 23167852 — intervention group
Group type: COMPARATOR
Intervention: User-Feedback strategy
Number of subjects: 51
Study 23167852 — intervention group
Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 51
Study 23167852 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction survey
Number of subjects: 51
Study 20625362 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 39
Study 20625362 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine 120 mg/day
Number of subjects: 39
Study 17646219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone, 2 mg/kg/d up to 60 mg, on days 1 to 5
Number of subjects: 24
Study 17646219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17646219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 24
Study 15142875 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1‐null genotype
Number of subjects: 114
Study 11161543 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglycerides (ST) emulsion
Number of subjects: 30
Study 11161543 — intervention group
Group type: COMPARATOR
Intervention: Long chain triglyceride (LCT) emulsion
Number of subjects: 30
Study 9831629 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat high cholesterol diet
Number of subjects: 18
Study 9831629 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat low cholesterol diet
Number of subjects: 18
Study 9831629 — intervention group
Group type: COMPARATOR
Intervention: Low fat low cholesterol diet
Number of subjects: 18
Study 9831629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol intake
Number of subjects: 18
Study 9831629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat intake
Number of subjects: 18
Study 9831629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol-induced percent change in LDL-C
Number of subjects: 18
Study 9831629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary cholesterol-induced percent change in HDL-C
Number of subjects: 18
Study 7853817 — intervention group
Group type: EXPERIMENTAL
Intervention: ditek
Number of subjects: 48
Study 7853817 — intervention group
Group type: COMPARATOR
Intervention: disodium cromoglycate (lomudal)
Number of subjects: 48
Study 7853817 — intervention group
Group type: COMPARATOR
Intervention: fenoterol (berotek)
Number of subjects: 48
Study 2506702 — intervention group
Group type: EXPERIMENTAL
Intervention: Neogluconin (2.5 mg)
Number of subjects: 25
Study 2506702 — intervention group
Group type: COMPARATOR
Intervention: Euglucon (5 mg)
Number of subjects: 25
Study 414402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 121
Study 414402 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiotepa
Number of subjects: 121